We have shown in models of cancer that PARPi-FL, a fluorescent PARP1-targeted small molecule, specifically binds to PARP1 with a similar affinity to Olaparib (Lynparza, Astra-Zeneca), an FDA-approved PARP1 inhibitor. The gene discussed is PARP1; the disease is cancer.